Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla
about
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.
P2860
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Rationale and design of the Ge ...... autologous stem cell transpla
@ast
Rationale and design of the Ge ...... autologous stem cell transpla
@en
type
label
Rationale and design of the Ge ...... autologous stem cell transpla
@ast
Rationale and design of the Ge ...... autologous stem cell transpla
@en
prefLabel
Rationale and design of the Ge ...... autologous stem cell transpla
@ast
Rationale and design of the Ge ...... autologous stem cell transpla
@en
P2093
P2860
P50
P921
P1433
P1476
Rationale and design of the Ge ...... with relapsed multiple myeloma
@en
P2093
Anna Jauch
Axel Nogai
Christina Kunz
Christof Scheid
Hans Martin
Hans W Lindemann
Ingo G H Schmidt-Wolf
Jana Schlenzka
Jens Hillengaß
P2860
P2888
P356
10.1186/S12885-016-2321-2
P407
P577
2016-04-25T00:00:00Z
P5875
P6179
1033573714